The cholecystokinin 2 receptor (CCK2R) increases proliferation of normal and neoplastic gastrointestinal cells and activates various mitogenic signaling pathways when stimulated by gastrin. To study the incidence of permanent activation of this receptor in tumorigenicity, a constitutively active mutant was generated by replacing residue Glu151 in the conserved E/DRY motif by Ala. Expression of the E151A-CCK2R mutant in NIH-3T3 cells causes ligand-independent activation of phospholipase C and ornithine decarboxylase, two enzymes critical for mitogenesis. Strikingly, the constitutive activity of this mutant was associated with dramatic alteration of NIH-3T3 cell morphology, enhanced cell proliferation and invasion. Moreover, injection of cells expressing E151A-CCK2R in nude mice resulted in the development of large and rapidly growing tumors. By contrast, none of these effects was observed with cells expressing the wildtype CCK2R, indicating that the tumorigenic properties of the E151A-CCK2R mutant is the result of its constitutive activation. To date, this is the first report that provides evidence for the high tumorigenic effect of a constitutively active CCK2R mutant, thus raising a potential role of the CCK2R in human cancer.
Introduction
The cholecystokinin 2 receptor (CCK2R), formerly named CCKB/gastrin receptor, belongs to the superfamily of G protein-coupled receptors (GPCR) that are characterized by seven transmembrane a-helical domains. This receptor has been shown to have growth-promoting effects on normal and neoplastic gastrointestinal cells when stimulated by gastrin. Its proliferative action was reported in pancreatic, gastric and colonic cancer cell lines as well as in cells outside the digestive system including small-cell lung cancer and other cell lines, such as NIH-3T3, Rat-1 and CHO, transfected with the CCK2R (Rozengurt and Walsh, 2001) . Interestingly, the CCK2R has been described to be well expressed in many cancers of different origin, while it is not present in the corresponding normal tissues (Reubi et al., 1997) , indicating that this receptor may have an important role in tumorigenicity. It is well demonstrated that the CCK2R activates various signaling pathways involved in cell growth and transformation, including phospholipase C (PLC), p42-p44 and p38 mitogen-activated protein kinases (Rozengurt and Walsh, 2001) . Additionally, the CCK2R regulates early growth-responsive genes as well as the biosynthesis and the activation of the proto-oncogene ornithine decarboxylase (ODC) in pancreatic cancer cells AR4-2J (Scemama et al., 1989; Todisco et al., 1995; Pyronnet et al., 1998) . In agreement with an important proliferative effect in vitro, the disruption of the CCK2R gene in mice results in severe atrophy of the gastric mucosa and a reduced density of enterochromaffin-like and parietal cells. Conversely, transgenic mice overproducing gastrin in the fundic epithelium exhibited hyperplasia of mucous cells (Rozengurt and Walsh, 2001) . Recently, it was reported that the transgenic expression of the CCK2R in mouse exocrine pancreas, a tissue that naturally expresses the CCK1R subtype, results in neoplasic transformation of acinar cells and consequent tumor formation in 10% of homozygote mice, highlighting the importance of the CCK2R in the development of pancreatic cancers (Clerc et al., 2002) . Another evidence for a role of the CCK2R in gastrointestinal cancer comes from the fact that the receptor and its natural ligand, gastrin, are upregulated in human colon and pancreatic adenocarcinoma, resulting in endocrine and autocrine stimulation (Caplin et al., 2000; Smith and Watson, 2000; Schmitz et al., 2001) . However, no study has examined yet the direct effects of overexpression or constitutive activation of the CCK2R on tumor generation in vivo.
There is accumulating evidence that constitutively active mutants of either GPCR or of protein partners of their signaling network can harbor oncogenic potential (Dhanasekaran et al., 1995; Radhika and Dhanasekar-an, 2001 ). Alterations of proteins mediating mitogenic signaling often induce aberrant cell growth and malignant transformation. Interestingly, a splice variant of the CCK2R isolated from human colorectal cancers and containing 69 additional amino acids in the third intracellular loop has been reported to exhibit constitutive activation of intracellular calcium release and cell proliferation. However, no relation between the constitutive activity of this mutant and colorectal cancer development has been reported (Hellmich et al., 2000) . Recently, the same mis-spliced CCK2R variant was identified in human pancreatic carcinoma. The authors have explored the molecular basis for this mis-splicing event; however, they did not report the tumorigenic effect of this variant (Ding et al., 2002) . The identification of constitutively active forms of TSH receptor in 30% of thyroid adenomas provided a direct link between GPCRs and human cancer (Parma et al., 1995) . More recently, sequences encoding functional GPCRs homologous to chemokine receptors have also been found in the genome of transforming viruses. The expression of Kaposi's sarcoma-herpesvirus-G proteincoupled receptor (KSHV-GPCR) has been shown to induce constitutive activation of phosphatidyl inositol production, cell transformation and tumor formation in nude mice (Bais et al., 1998) . This receptor is considered to be an etiologic agent of Kaposi's sarcoma (Yang et al., 2000) . In the chemokine receptor CXCR2, the mutation of the Asp of the conserved DRY motif was reported to induce its constitutive activation and transformation similar to that observed in KSHV-GPCR-transfected cells, emphasizing the importance of the Asp of the DRY sequence (Burger et al., 1999) . The Asp residue, that may be a Glu in some receptors (D/ERY motif), is likely to play a crucial role in receptor activation as its mutation often results in constitutive activation of PLC or adenylyl cyclase pathways (Cohen et al., 1993; Scheer et al., 1996; Morin et al., 1998; Rasmussen et al., 1999; Alewijnse et al., 2000) . An ERY motif is also conserved at the end of the transmembrane domain 3 of the CCK2R. Considering the key role of the ERY motif in GPCR activation and the effect of CCK2R on cell proliferation, we sought to examine the consequences of the Glu151 to Ala mutation on the properties of human CCK2R. Our results demonstrate that expression of the E151A-CCK2R mutant in NIH-3T3 cells causes high constitutive activation of PLC and ODC, two enzymes critical for mitogenesis. Strikingly, the constitutive activity of the mutant was associated with dramatic alteration of cell morphology, enhanced agonist-independent proliferation and invasion and consequent tumor generation in nude mice. To date, this is the first report that provides support for the tumorigenic effect of a constitutively active mutant of CCK2R.
Results
To investigate whether the E151A mutation in the conserved ERY motif results in constitutive activation of the CCK2R, NIH-3T3 fibroblasts expressing either wild-type or mutant CCK2R were established. NIH-3T3 cells have been chosen because they represent a model of reference to explore the transformation or tumorigenic potential of a heterologous gene or a construct. In addition, expression of the CCK2R in cells where it is not normally expressed may be characteristic of a pathological situation since the CCK2R has been described to be well expressed in many cancers of different origin, while it is not present in the corresponding normal tissues (Reubi et al., 1997) . Since the CCK2R is primarily coupled to PLC activation in different cell lines, including fibroblasts (Wank, 1998) , agonist-independent IP production was first examined. Then, we measured whether the E151A-CCK2R mutant was able to stimulate ODC activity. Indeed, this protooncogene has been reported to be activated by the CCK2R in pancreatic cancer cells, AR4-2J, and to be permanently stimulated in cells transformed by various oncogenes (Holtta et al., 1988; Scemama et al., 1989; Sistonen et al., 1989; Holtta et al., 1993) .
The E151A-CCK2R mutant constitutively activates PLC NIH-3T3 cells were transfected and 10-20 individual neomycin-resistant clones were randomly picked. The expression of wild-type or mutated receptors as well as CCK affinity was assessed by performing binding experiments on whole cells with radiolabeled CCK. The affinities (K d ) and maximal binding capacities (B max ) for each clone are reported in Table 1 . Clones expressing similar levels of wild-type (WT4 and WT5) or mutant receptor (M1 and M40) were selected for further studies. In addition, one clone expressing a twofold higher level of the mutant receptor (M9), as well as two clones (C20 and C50) and a pool of cells (pool) transfected with empty PRFneo vector were chosen. The selected clones were then tested for basal or CCKstimulated IP production ( Table 1 ). The clones expressing the mutant receptor (M1, M40 and M9) bound CCK with a slightly increased affinity as compared to those expressing the wild-type receptor (WT4 and WT5). These data are consistent with other studies on constitutively active receptors showing that agonists display increased affinity for constitutively active receptors that reflect conformational selection caused by the preferential binding of the agonist to the activated state of the receptor (Hunyady et al., 2003) . The basal IP production in clones expressing the mutant was higher than in wild-type and control clones. It was two times more in M9 than in M1 or M40 clones, indicating that basal IP production correlated well with the level of expression of E151A-CCK2R and that the mutated receptor harbored constitutive activity on the IP pathway. Measurement of PLC activity indicated that CCK stimulated IP production with a similar potency in all clones; however, IP production induced by maximal concentration of agonist was reduced (60% decrease) in all clones expressing the mutated receptor. These data are consistent with numerous studies showing that agonist stimulation of constitutively active receptors can display a large panel of responses in comparison with the wild-type receptor. The existence of intermediate active states has been proposed to describe the activation of GPCRs. These intermediate states that might couple to G proteins with variable efficiencies, could explain the distinct responses observed with constitutively active mutants that would reflect one of these intermediate active states (Gether et al., 1998 (Gether et al., , 2000 Hunyady et al., 2003) . The selective CCK2R antagonist, RPR048, was able to inhibit the constitutive activity of the mutated receptor in a concentrationdependent manner in all the clones expressing the mutant, indicating that this compound behaves as an inverse agonist on the receptor mutant (Kenakin, 2002) . Similar inhibition was observed with 1-mm RPR048 in all the clones expressing the mutant (not shown). As illustrated in Figure 1 for the M1 clone, RPR048 acted with an EC 50 of 2.6270.25 nm and inhibited 82% of the basal IP production at 1-mm. The fact that this compound is not able to completely inhibit the basal IP production to the level measured in control cells indicates that this compound acts as a partial inverse agonist on permanent IP production.
The E151A-CCK2R mutant constitutively activates ODC
We subsequently sought whether the wild-type or mutated receptors stimulate ODC in NIH-3T3 cells in response to gastrin, and whether the mutant receptor permanently activates this enzyme. In cells expressing the wild-type (WT5 clone) or the mutated receptor (M1 clone), the stimulation of ODC activity by gastrin was time dependent and reached a maximum at 4 h ( Figure 2a ). In contrast, no increase in ODC activity was observed in control cells (C20 clone). The basal ODC activity measured in the M1 clone was eightfold higher than that in the WT5 or C20 clones (Figure 2a ), indicating an important constitutive activation of this enzyme in cells expressing the E151A-CCK2R mutant. This result was confirmed by measuring basal ODC activity in other clones. Indeed, only clones expressing the E151A-CCK2R mutant displayed permanent ODC activation ( Figure 2b ). RPR048 was able to decrease this permanent ODC activity. As shown in Figure 2b , 1-mm RPR048 inhibited around 70% of the basal ODC activity, indicating that RPR048 is a partial inverse agonist on constitutive ODC activity.
Morphologic transformation of cells expressing the E151A-CCK2R mutant
Constitutive activity of the E151A-CCK2R mutant was associated with morphologic transformation of NIH-3T3 cells. As shown in Figure 3 , all clones expressing the mutated receptor form (M1, M40 and M9) displayed spindle-shaped and highly refractile morphology, with long protrusions and pseudopodia, likely reflecting a reorganization of the cytoskeleton. In contrast, clones expressing the wild-type form (WT4 and WT5) exhibited a flatter, nonrefractile morphology as control cells (C20). These morphological changes were due to 
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Figure 1 Effect of the nonpeptide antagonist RPR048 on basal IP production. NIH-3T3 clones expressing the CCK2R (WT5) or the E151A-CCK2R mutant (M1) were treated for 1 h with increasing concentrations of RPR048 and IP production was assessed as described in 'Materials and methods'. Results are expressed as fold induction over basal IP production in control cells (pool of cells transfected with the empty vector) and are means7s.e. of three experiments performed in duplicate Constitutive activation of the cholecystokinin 2 receptor and tumor C Gales et al constitutive activity of the mutant, since exposure of the M1 clone to 1-mm RPR048 during 48 h completely reversed this phenotype (Figure 4 ). In contrast, no effect of RPR048 was observed on the WT5 clone. It has to be noted that the reversion of cell morphologic transformation by RPR048 was not associated with an inhibition of cell proliferation, since cells continued to proliferate in the presence of RPR048 (Figure 4 ). These results may be explained by the fact that RPR048 inhibited only partially constitutive IP production and ODC activation (Figure 1 and 2b), and thus suggest that different signaling pathways contribute to cell growth and morphological changes.
Expression of the E151A-CCK2R mutant affects NIH-3T3 cell growth
Since a major characteristic of malignant cells is a higher capacity to proliferate, we evaluated agonist-independent proliferation of the different NIH-3T3 clones. As shown in Figure 5 , WT5 and C20 clones displayed no significant difference in proliferation rate and stopped growing after day 3. Compared to WT5, M1 showed enhanced proliferation, although both clones express the receptor to a similar level. Its growth surpassed that of WT5 after day 2 to reach a final cell density 1.6-fold higher than that of WT5 or C20 clones by day 4. Interestingly, the M9 clone that expresses twice more receptors than M1, displayed a more prolonged growth so that the final cell density was 2.3-fold higher than that of WT5 or C20 clones by day 6, indicating that proliferation of cells expressing the mutant is linked to its constitutive activity. Together, these results indicate that the E151A-CCK2R mutant expression in NIH-3T3 cells induces enhanced agonist-independent cell proliferation. Constitutive activation of the cholecystokinin 2 receptor and tumor C Gales et al exhibited the histomorphological features of fibrosarcoma (panel 1). Moreover, they displayed high mitotic activity (panel 2) and abundant blood vessels throughout the tissues (panel 3). All these results indicate that the E151A-CCK2R mutant is highly tumorigenic in vivo.
NIH-3T3 cells expressing the E151A-CCK2R mutant display enhanced invasive capacity
In light of these results, the invasiveness potential of NIH-3T3 cells expressing the constitutively active mutant was assessed and compared to that of cells expressing the wild-type receptor. Cells seeded on the top of a highly concentrated matrigel matrix were first subjected to morphological examination. After one day, cells from M1 clone were assembled into complex branching tubular networks (Figure 7a ), as described for carcinoma cells displaying invasive and metastatic capacity (Albini et al., 1987; Zhuge and Xu, 2001) . After 2 weeks, most of the matrigel was invaded and degraded (not shown). Cells from WT5 and C20 clones failed to exhibit this organized structure; instead they stop growing and remained isolated (Figure 7a ). We then evaluated the invasion ability of the M1, WT5 and C20 clones through a porous filter coated with low concentrated matrigel. Compared to WT5 or C20, M1 clone displayed an 8.7-fold greater capacity to invade the basement matrix (Figure 7b ). Together, these results provide strong evidence that NIH-3T3 cells expressing the E151A-CCK2R mutant exhibit high invasive capacity and thus display the characteristic of tumorigenic cells.
Discussion
In the present study, we showed that the mutation of the Glu151 located in the conserved ERY motif to Ala results in the constitutive activation of the CCK2R. In addition, we demonstrated that expression of the E151A-CCK2R mutant in NIH-3T3 cells enhances proliferation and induces the formation of large and rapidly growing tumors in nude mice. All tumors displayed rich neovascularization and significant mitotic activity, characteristic of high-grade tumors. The oncogenic potential of GPCRs has been examined for the serotonin 1C, the a1b-adrenergic and the m1, m3 and m5 muscarinic acetylcholine receptors. These receptors have been reported to transform NIH-3T3 cells in an agonist-dependent manner (Julius et al., 1989; Allen et al., 1991; Gutkind et al., 1991) . Moreover, three transforming GPCRs, Mas, G2A and PAR-1, have been identified in biological screen for proteins that cause fibroblast transformation. The transforming activity of these receptors was shown to be associated with overexpression, but not with mutational activation (Whitehead et al., 2001) . So far, very few reports investigated the oncogenic potential of constitutively active GPCRs; it is, however, well documented that several members of this class of receptors exist in an active form in the absence of agonist. Activating mutations in GPCR have been associated with human tumors and oncogenic transformation of NIH-3T3 cells (Allen et al., 1991; Parma et al., 1995; Bais et al., 1998; Estep et al., 2003) . Of note, in the cases of the a1b-adrenergic receptor and viral GPCR-KSHV, tumorigenicity was observed only when inoculating mice with foci-derived transformed cells, which were obtained after several weeks of culture in the presence (a1b-adrenergic) or the absence (GPCR-KSHV) of agonist (Allen et al., 1991; Bais et al., 1998) . In the present study, subconfluent cells directly injected into nude mice were able to form tumors, showing that the E151A-CCK2R mutant harbors strong tumorigenic property.
The neoplastic transformation process is, to a large extent, controlled through the activation of mitogenic signaling pathways. In the present study, the constitutive activity of the E151A-CCK2R mutant in NIH-3T3 cells was demonstrated on IP production. Activation of PLCb and subsequent stimulation of PKC and mobilization of intracellular calcium is known to play a crucial role in mitogenesis. Coupling to Gq proteins and activation of PLCb have been well described for the CCK2R in different normal and cancer cell lines (Wank, 1998; Gales et al., 2000) . In the tumor-derived pancreatic cell line AR4-2J, inhibition of PKC abolished cell proliferation mediated through activation of the CCK2R by gastrin (Stepan et al., 1999) . Several GPCRs activating PLCb, including muscarinic m1, m2 and m5, a1b-adrenergic or serotonin 5HT1c receptors, have been shown to stimulate DNA synthesis and to induce agonist-dependent cell transformation and/or tumorigenicity (Julius et al., 1989; Allen et al., 1991; Gutkind et al., 1991) . Such effects were not reported with the m2 and m4 muscarinic subtypes that inhibit adenylyl cyclase Invasiveness of NIH-3T3 cells expressing the CCK2R (WT5), the E151A-CCK2R mutant (M1) or transfected with the empty vector (C20). (a) Cells were embedded on a thick matrigel layer as described in 'Materials and methods'. A representative clonal population of cells photographed under phase-contrast microscopy after 48 h is shown. Note that cells from the M1 clone, but not from the WT5 or C20 clones, were assembled into complex branching tubular networks. (b) Cell invasion was assayed using matrigel-coated Boyden diffusion chambers as described in 'Materials and methods'. After 48 h, cells on the lower surface of the filters were stained and counted under a phase-contrast microscope. Each assay was carried out in triplicate and repeated three times (Gutkind et al., 1991) , indicating the key role of PLC and PKC in these processes. The constitutive activity of the E151A-CCK2R mutant was also confirmed by its ability to cause permanent activation of the protooncogene ODC. In tumoral AR4-2J cells, ODC activity and biosynthesis are enhanced as a result of the CCK2R activation by gastrin (Scemama et al., 1989; Pyronnet et al., 1998) . This enzyme has a key role in cell cycle by regulating the production of polyamines that stimulate DNA, RNA and protein synthesis and stabilize membrane and cytoskeletal structures. Moreover, it was reported to have a critical role in cell transformation (Auvinen et al., 1992) . Constitutively elevated ODC activity has been demonstrated in cells transformed by potent oncogenes such as v-src, neu and ras, as well as by different chemical carcinogens (Holtta et al., 1988 (Holtta et al., , 1993 Sistonen et al., 1989) . Moreover, NIH-3T3 cells overproducing ODC were reported to develop highgrade tumors in nude mice (Auvinen et al., 1997) . Thus, the high constitutive activation of this enzyme in NIH-3T3 cells expressing the E151A-CCK2R mutant is consistent with the fact that injection of these cells into nude nice results in the development of high-grade tumors. However, the signal transduction pathways that are responsible for tumorigenicity of the constitutive mutant remain to be identified. Interestingly, the expression of the E151A-CCK2R mutant was shown to be associated with morphologic transformation. Indeed, striking differences in cell morphology were observed between NIH-3T3 cells expressing the mutant and the wild-type receptor. On plastic substrate, cells expressing the mutant displayed elongated shape, protrusions and pseudopodia, which are characteristic of an invasive and migratory phenotype. This morphologic transformation was dependent on the constitutive activity of the E151A-CCK2R mutant, since it was totally reversed by treatment with the inverse agonist RPR048. On matrigel substrate, only cells expressing the mutant receptor were assembled into complex branching tubular network. This branching phenotype may be of pathological relevance: (i) it has been associated with the invasive and metastatic capacities of several cancerous cells or of NIH-3T3 cells transfected with various oncogenes such as mutated cras, v-mos, v-sis or v-fos (Melchiori et al., 1990) ; (ii) it is not found in normal cells or low-grade carcinoma (Albini et al., 1987; Zhuge and Xu, 2001 ). However, induction of a branching morphogenesis is not a peculiar property of the E151A-CCK2R mutant, since it was recently shown that CCK2R stimulation by gastrin promotes organization of gastric cells in tubular structures (Pagliocca et al., 2002) . As the malignancy of cancer cells lies in their capacity to invade the extracellular matrix and to form metastasis, the invasiveness potential of the clones was evaluated. In agreement with their morphologic phenotype, NIH-3T3 cells expressing the constitutive mutant displayed a high capacity to invade through matrigel, as compared to cells expressing the wild-type receptor. Altogether, these results establish that constitutive activation of the CCK2R, through a genetically engineered mutation, is directly responsible for the development of tumors and might influence their progression and malignancy by promoting cell invasion and metastasis.
In the literature, it is well described that many constitutively active receptors display increased instability, lower expression or absence of internalization (Parnot et al., 2002) . These features can limit their expression in transgenic animals. Indeed, development of transgenic mice expressing constitutively active mutants as animal models of heart diseases did not produce any specific cardiac phenotype with a b2-adrenergic constitutively active mutant, because the mutant protein was unstable and not expressed at the cell surface of cardiomyocytes. Stabilization of the mutant by different b2-specific ligands was able to unmask the phenotype (Samama et al., 1997) . Interestingly, the transient expression of the E151A-CCK2R mutant in COS cells indicates that it is not unstable as it was expressed at a similar level as the wild-type receptor (data not shown). In addition, its internalization rate was not affected and was found to be similar to that we determined in NIH-3T3 cells expressing the wild-type CCK2R (Pohl et al., 1997) . Thus, this mutant represents an interesting tool to study in vivo the activated CCK2R. Expression of this mutant in transgenic mice to explore its tumorigenic potential in different target organs where the CCK2R mediates important physiological functions remains an interesting goal for coming years, as it should allow one to link the permanent activation of this receptor with development of cancer. It would also be important to search if such activating mutations occur in human cancers.
Material and methods

Material
The sulfated C-terminal nonapeptide of CCK (Thr 28 , Nle 31 -CCK25-33) was synthesized, conjugated with Bolton-Hunter reagent, purified and radioiodinated as described previously (Moroder et al., 1981; Fourmy et al., 1989) . This CCK2R ligand is referred as [ 125 I]-BH-CCK-9 throughout the manuscript. The RPR048 compound was kindly provided by Aventis Pharma (France). Mutant CCK2R cDNA was obtained from wild type by oligonucleotide-directed mutagenesis as described previously (Gales et al., 2000) .
Cell culture and transfection
NIH-3T3 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 4.5 g/l glucose and supplemented with 10% fetal calf serum. Plasmids for the expression of either wild-type (pRFneo-CCK2R) or mutant (pRFneo-E151A-CCK2R) human CCK2R and empty pRFneo were transfected in NIH-3T3 cells by using Fugene 6 transfection reagent (Roche). Stable transfectants were selected in the presence of 1 mg/ml neomycin (G418) and antibiotic resistant clones were collected individually. G418-resistant cells transfected with empty pRFneo will be referred as control cells.
Binding assay
Binding was performed by incubating whole cells with 50 pm of [ 125 I]-BH-CCK-9 and with, or without, increasing concentrations of unlabeled CCK9 for 1 h at 371C. Nonspecific binding (determined in the presence of 1-mm CCK-9) was less than 10% of the total. Binding data were analysed using the nonlinear, least-squares, curvefitting computer program, Ligand (Munson and Rodbard, 1980) and GraphPad Prism (Software).
Measurement of total inositol phosphate accumulation
Cells were incubated overnight in the presence of 2 mCi/ ml myo-2-[ 3 H]inositol (18.6 Ci/mmol) (Dupont NEN). Total IP accumulation was measured after stimulation by the indicated concentration of CCK-9 for 1 h at 371C as described previously (Silvente-Poirot et al., 1999; Gales et al., 2000) . EC 50 was calculated using the GraphPad Prism Program.
Measurement of ODC activity
Cells were rinsed twice with ice-cold PBS, scrapped in lysis buffer (50-mm Tris-HCl, pH 7.4; 1-mm EDTA; 1-mm DTT), and subjected to two freeze-thaw cycles. Lysates were cleared at 12 000 g for 10 min. Equal amounts of total protein were incubated in 96-well microtiter plates with 2.5 mCi of [ 14 C]ornithine (Amersham) for 1 h at 371C. The generated CO 2 was trapped on a covering 3MM paper saturated with a solution of barium hydroxide. The paper was dried, exposed to a phosphoimager plate and radioactivity was quantified (Image QuaNT, Molecular Dynamics).
Cell growth assay
Cells were plated in 35-mm diameter dishes at a density of 10 5 cells per dish and grown in DMEM 4.5 g/l glucose, supplemented with 10% fetal calf serum. All the dishes received fresh medium every day. At the indicated time, cells were trypsinized and counted with a Coulter counter (Coulter Electronics).
Tumorigenesis
Cells expressing the wild-type CCK2R or the mutant E151A-CCK2R and control cells were trypsinized, washed and resuspended in a serum-free medium. Cells (6 Â 10 6 cells/0.5 ml) were injected into the flank of 5-week-old female nu/nu Swiss mice (IFFA Credo). Animals were monitored at 4-day intervals for the development of tumors over a 4-6-week period. Tumors were rapidly collected, fixed for 24-48 h at 41C in 4% paraformaldehyde and embedded in paraffin for histological analysis. Sections from paraffin blocks were stained with hematoxylin-eosin, mounted in glycergel and used for tissue histology analysis.
Cell spreading on matrigel
Cell-spreading assay was performed as described by others (Albini et al., 1987; Melchiori et al., 1990) . Growth factor-reduced Matrigel s matrix (Becton Dickinson) (10 mg/ml) was poured into 25-mm diameter tissue culture wells and polymerized at 371C for 1 h. A cell suspension (10 5 cells) in DMEM 4.5 g/l glucose, supplemented with 10% fetal calf serum, was seeded onto the top of the gel and incubated at 371C. Cell morphology was examined under phase-contrast microscope after 48 h.
Invasion assay
Invasion assays were carried out in Boyden chambers (Nunc). Polycarbonate filters (8-mm diameter, 8-mm pore size) were coated with growth factor-reduced Matrigel s matrix (Becton Dickinson) (12.5 mg/filter from a 250 mg/ml solution of matrigel in cold DMEM 4.5 g/l glucose). Cells were trypsinized, washed and resuspended in a serum-free medium supplemented with 0.1% BSA and then layered on top of the matrigel (10 5 cells/chamber). The bottom of the chamber was filled with DMEM 4.5 g/l glucose. The chambers were incubated at 371C. After 48 h, cells that had invaded the matrigel and were attached to the lower surface of the filters were fixed, stained with diff-Quick staining kit (Fisher Scientific) and counted under the microscope (image-analysis system Visio-Lab; Biocom Paris).
